Title
Category
Credits
Event date
Cost
Long COVID in Children and Adolescents
  • Child and Adolescent Psychiatry
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Long COVID symptoms are both physical and mental in nature among children and adolescents and have the potential to affect long-term functioning and increase the overall burden on health care delivery.
Treatment-Resistant Mood Disorders in LGBTQ People: A Retrospective Study of Clinical Features and Response to Electroconvulsive Therapy
  • Mood Disorders
  • Depression
  • Electroconvulsive Therapy
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
In this chart review, LGBTQ people with treatment-resistant mood disorders had clinical features linked to worse outcomes, but their improvement with ECT was similar to that seen in non-LGBTQ patients.
Suicide Risk in a National VA Sample: Roles of Psychiatric Diagnosis, Behavior Regulation, Substance Use, and Smoking
  • Bipolar Disorder
  • Schizophrenia/ Schizoaffective Disorders
  • Smoking
  • Substance Use Disorders
  • Suicide
  • Veterans and Military Issues
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Predicting suicide is difficult, as suicidal behavior is not linked solely to any single behavior or psychiatric diagnosis. This study compared risk of suicidal behavior among a transdiagnostic sample of Veterans with varying disorders and behaviors.
Facilitating Treatment Initiation in Early-Stage Alzheimer Disease
  • Primary Care
  • Patient/Physician Communication
  • Neuroimaging
  • Alzheimer Disease
  • Dementia
  • Integrated Care
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Many new therapies for early-stage AD have made their way onto the scene that can delay onset of the disease and/or slow down progression. Find out the how, what, when to better treat your patients with AD from specialists in the field.
Timely Diagnosis of Alzheimer Disease
  • Primary Care
  • Neuroimaging
  • Alzheimer Disease
  • Dementia
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Early-stage diagnosis of Alzheimer disease leads to prompt treatment initiation and better patient QoL. Learn about new guidelines and technology advances and what’s on the horizon from authorities in the field.
Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study
  • Psychotic Disorders
  • Substance Use Disorders
  • COVID-19
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Identifying risk factors that predispose individuals to negative COVID-19 outcomes is important. The current study examined the association between substance use disorders, psychiatric diagnosis, and COVID-19–related clinical outcomes.
The Co-occurrence of Gastrointestinal Symptoms and Psychosis: Diagnostic Considerations
  • Psychotic Disorders
  • Gastroenterology
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
There are numerous clinical scenarios in which gastrointestinal and psychotic symptoms commonly co-occur; thus, it is important that both psychiatrists and primary care physicians have a familiarity with the differential diagnosis.
A Systematic Review of Complex Polypharmacy in Bipolar Disorder: Prevalence, Clinical Features, Adherence, and Preliminary Recommendations for Practitioners
  • Mood Disorders
  • Bipolar Disorder
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Do you tend to use combination pharmacotherapy regimens in patients with bipolar disorder? Will patients receiving 3 or more drugs have better outcomes?
Improving Standards of Care in Type 2 Diabetes with Chronic Kidney Disease: Integrating the Non-Steroidal Mineralocorticoid Antagonist Class in Cardiorenal Medicine
  • Renal Disease
  • Primary Care
  • Patient/Physician Communication
  • Side Effects
  • Cardiology
  • Metabolic Disorders
  • Diagnostic Tools
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
How to screen UACR and eGFR levels, implement selective non-steroidal MRA therapies, and mitigate the risk of hyperkalemia to prevent CKD disease progression
Like a Game of Chess, Every Move Matters: The Role of Antibodies in the Myasthenia Gravis Treatment Landscape
  • Myasthenia Gravis
  • AMA PRA Category 1 Credit™
  • Participation
$0.00
Symptoms and disease pathophysiology of myasthenia gravis (MG) vary considerably with each patient, and their individual preferences and priorities add to the need for individualized treatment of this autoimmune disease. Research in MG has grown substantially in recent years. New treatments have the potential of being both effective and well tolerated, addressing the trade-off of choosing either efficacy or tolerability when selecting treatments. Promising investigational treatments that may become available in the future may allow more patients than ever before to achieve an asymptomatic state, with the ultimate goal being to turn off abnormal antibody production.

Pages